Johnson & Johnson stock (US4781601046): Key holdings in major ETFs amid market volatility

Johnson & Johnson, a diversified healthcare giant, continues to feature prominently in investor portfolios, including as a top holding in the Invesco S&P 500 Momentum ETF (SPMO). Recent market discussions underscore its role amid rising inflation fears projected for 2026. The stock's presence in such funds reflects its defensive qualities in pharmaceuticals, medical devices, and consumer health products.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Johnson & Johnson: core business model

Johnson & Johnson operates through three main segments: Innovative Medicine, MedTech, and Consumer Health. The Innovative Medicine unit focuses on pharmaceuticals for oncology, immunology, neuroscience, cardiovascular, and infectious diseases. MedTech provides surgical equipment, orthopaedics, and vision care. Consumer Health includes brands like Tylenol and Neutrogena. This diversified model reduces risk from any single area, appealing to US investors seeking stability in healthcare.

The company's global reach spans over 60 countries, with significant revenue from the US market. Its business model emphasizes R&D investment, with billions allocated annually to pipeline development. For US investors, JNJ's NYSE listing and exposure to the world's largest healthcare market make it a core holding.

Main revenue and product drivers for Johnson & Johnson

Key revenue drivers include blockbuster drugs like Darzalex for multiple myeloma and Stelara for immunology, which generated substantial sales in recent quarters. MedTech growth comes from products like the Ottava robotic surgery system. Consumer staples provide steady cash flow. In Q4 2024 results published January 2025, operational sales grew 5.3%, per J&J IR as of 01/22/2025.

US sales represent about 50% of total revenue, tying JNJ closely to American healthcare spending trends. The spin-off of Kenvue in 2023 streamlined operations, boosting focus on higher-margin pharma and devices.

Why Johnson & Johnson matters for US investors

JNJ's dominant position in US healthcare, including Medicare and hospital supply chains, links it directly to domestic policy and spending. As a Dividend King with over 60 years of increases, it offers yield stability amid volatility. Its NYSE trading in USD facilitates easy access for retail investors.

Conclusion

Johnson & Johnson maintains its stature as a healthcare cornerstone, featured in key ETFs and supported by diversified revenue streams. While markets grapple with 2026 inflation outlooks, the company's US-centric exposure and innovation pipeline provide continuity. Investors track upcoming earnings and pipeline updates for further insights.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.